{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:54Z","timestamp":1790812134489,"version":"4.1.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.eprac.2025.07.014","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T11:51:29Z","timestamp":1757677889000},"page":"1207-1238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Dyslipidemia \u2013 2025 Update"],"prefix":"10.1016","volume":"31","author":[{"given":"Shailendra B.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Maria","family":"Belalcazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samina","family":"Afreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Balderas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Karpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos I.","family":"Ponte-Negretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Rajpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2025.07.014_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5334\/gh.1288","article-title":"The heart of the world","volume":"19","author":"Di Cesare","year":"2024","journal-title":"Glob Heart"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.014_bib2","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.014_bib4","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.014_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"24","key":"10.1016\/j.eprac.2025.07.014_bib6","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.014_bib8","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.eprac.2025.07.014_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.014_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100630","article-title":"Discrepancy in Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence in a Large Northern California Cohort","volume":"4","author":"Rodriguez","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.eprac.2025.07.014_bib13","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.57187\/s.3735","article-title":"Prognostic impact of carotid plaque imaging using total plaque area added to SCORE2 in middle-aged subjects: the ARteris Cardiovascular Outcome (ARCO) cohort study","volume":"154","author":"Romanens","year":"2024","journal-title":"Swiss Med Wkly"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.014_bib14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/eurjpc\/zwad139","article-title":"Carotid ultrasound and systematic coronary risk assessment 2 in the prediction of cardiovascular events","volume":"30","author":"Bao","year":"2023","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib154","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jcmg.2022.03.013","article-title":"Atherosclerotic disease risk stratification using ultrasonographic measurements of plaque","volume":"15","author":"Nicolaides","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.014_bib15","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1186\/s12889-022-13944-w","article-title":"Evaluation of cardiovascular diseases risk calculators for CVDs prevention and management: scoping review","volume":"22","author":"Badawy","year":"2022","journal-title":"BMC Public Health"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.014_bib16","first-page":"1210","article-title":"Simplified Canadian definition for familial hypercholesterolemia","volume":"34","author":"Ruel","year":"2018","journal-title":"Can J Cardiol"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.014_bib17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"21","key":"10.1016\/j.eprac.2025.07.014_bib18","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/CIRCULATIONAHA.117.032321","article-title":"Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999-2014)","volume":"137","author":"Bucholz","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib19","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eprac.2025.07.014_bib24","series-title":"Evidence-Based Management of Lipid Disorders","first-page":"217","article-title":"Sitosterolemia: xenophobia for the body","author":"Patel","year":"2010"},{"key":"10.1016\/j.eprac.2025.07.014_bib25","series-title":"Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease","first-page":"365","article-title":"Cerebrotendinous xanthomatosis","author":"Larson","year":"2025"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.014_bib26","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jpedsurg.2010.06.030","article-title":"Differential diagnosis of tendon tumors: xanthomas caused by hyperlipidemia in children","volume":"45","author":"Reichwaldt","year":"2010","journal-title":"J Pediatr Surg"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamacardio.2019.5954","article-title":"Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease","volume":"5","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.014_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacl.2024.09.008","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","volume":"19","author":"Hegele","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.eprac.2025.07.014_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score.\"","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.014_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in hypertriglyceridemic pancreatitis: an update","volume":"48","author":"Scherer","year":"2014","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib33","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jacl.2018.09.006","article-title":"The spectrum of type III hyperlipoproteinemia","volume":"12","author":"Sniderman","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.eprac.2025.07.014_bib34","article-title":"Dysbetalipoproteinemia: focus on a neglected lipid disorder","author":"Berberich","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.014_bib35","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/pds.1448","article-title":"High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate","volume":"16","author":"Keidar","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.atherosclerosis.2013.11.043","article-title":"Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease","volume":"232","author":"Gylling","year":"2014","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.014_bib37","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0025-6196(11)63144-3","article-title":"Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels","volume":"78","author":"Katan","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib40","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jacl.2019.08.003","volume":"13","author":"Kirkpatrick","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00002018-200124060-00003","article-title":"Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels","volume":"24","author":"Mantel-Teeuwisse","year":"2001","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib42","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3904\/kjim.2024.156","article-title":"2024 KSoLA consensus on secondary dyslipidemia","volume":"39","author":"Won","year":"2024","journal-title":"Korean J Intern Med"},{"issue":"Suppl 3","key":"10.1016\/j.eprac.2025.07.014_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib44","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacl.2023.05.099","article-title":"Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association","volume":"17","author":"Kirkpatrick","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"9943","key":"10.1016\/j.eprac.2025.07.014_bib45","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.014_bib46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","article-title":"Current knowledge of hypertriglyceridemic pancreatitis","volume":"25","author":"Valdivielso","year":"2014","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.amjmed.2021.12.006","article-title":"Prevention and management of hypertriglyceridemia-induced acute pancreatitis during pregnancy: a systematic review","volume":"135","author":"Gupta","year":"2022","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.014_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101659","article-title":"Approach to patients with hypertriglyceridemia","volume":"37","author":"Chait","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib49","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3390\/nu14051104","article-title":"The effect of dietary interventions on hypertriglyceridemia: from public health to molecular nutrition evidence","volume":"14","author":"Luna-Castillo","year":"2022","journal-title":"Nutrients"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2025.07.014_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Associate of Clincial Endocrinologists and American College of Endocrinology guideilnes for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.014_bib51","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: U.S. Preventive Services Task Force recommendation statement","volume":"328","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib52","first-page":"474","article-title":"Ezetimibe plus statin combination versus double-dose statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk: a comprehensive systematic review and meta-analysis of 47 randomized controlled trials","volume":"38","author":"Mahmoud","year":"2025","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.eprac.2025.07.014_bib53","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf399","article-title":"The ACS EuroPath survey series: time trends in lipid management after an acute coronary syndrome","author":"Laufs","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"15","key":"10.1016\/j.eprac.2025.07.014_bib54","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","article-title":"Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry","volume":"85","author":"Leosdottir","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.014_bib55","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","article-title":"Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Guedeney","year":"2019","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.eprac.2025.07.014_bib56","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/eurjpc\/zwaa093","article-title":"Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis","volume":"28","author":"Khan","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"25","key":"10.1016\/j.eprac.2025.07.014_bib57","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2025.07.014_bib58","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","article-title":"Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry","volume":"85","author":"Leosdottir","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.014_bib59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"3 suppl","key":"10.1016\/j.eprac.2025.07.014_bib60","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A clinician\u2019s guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"21","key":"10.1016\/j.eprac.2025.07.014_bib61","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.014_bib62","first-page":"1006","article-title":"Can alternate-day Statin regimen minimize its adverse effects on muscle and tendon? A systematic review","volume":"69","author":"Muhammad","year":"2019","journal-title":"J Pak Med Assoc"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib63","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3138\/ptc.2012-65","article-title":"Statin-induced rhabdomyolysis: a comprehensive review of case reports","volume":"66","author":"Mendes","year":"2014","journal-title":"Physiother Can"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib64","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.rdc.2022.02.004","article-title":"Statin-associated myalgias and muscle injury-recognizing and managing both while still lowering the low-density lipoprotein","volume":"48","author":"Mammen","year":"2022","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib65","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.014_bib66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.014_bib67","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.014_bib68","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Non-fasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"19","key":"10.1016\/j.eprac.2025.07.014_bib69","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib70","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib71","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.014_bib72","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.014_bib73","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1161\/01.CIR.96.12.4211","article-title":"Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)","volume":"96","author":"Miettinen","year":"1997","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.014_bib74","doi-asserted-by":"crossref","first-page":"M859","DOI":"10.1093\/gerona\/58.9.M859","volume":"58","author":"Suryadevara","year":"2003","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.014_bib75","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-129-9-199811010-00002","article-title":"Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial","volume":"129","author":"Lewis","year":"1998","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1016\/j.eprac.2025.07.014_bib76","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"issue":"9326","key":"10.1016\/j.eprac.2025.07.014_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"9841","key":"10.1016\/j.eprac.2025.07.014_bib78","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.014_bib79","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamainternmed.2017.1442","article-title":"Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial","volume":"177","author":"Han","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eprac.2025.07.014_bib80","article-title":"Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study","volume":"362","author":"Ramos","year":"2018","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib81","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"17","key":"10.1016\/j.eprac.2025.07.014_bib82","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib83","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the pharmacologic management of adults with dyslipidemia","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2025.07.014_bib84","article-title":"Changes in blood lipids following initiation of gender affirming hormone therapy: a systematic review and meta-analysis","volume":"36","author":"Gosiker","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.014_bib85","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2017-01643","article-title":"Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis","volume":"102","author":"Maraka","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib86","doi-asserted-by":"crossref","first-page":"H861","DOI":"10.1152\/ajpheart.00299.2022","article-title":"Gender-affirming estrogen therapy route of administration and cardiovascular risk: a systematic review and narrative synthesis","volume":"323","author":"Turino Miranda","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.014_bib87","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/nutrit\/nuad003","article-title":"Lipid profile and risk of cardiovascular disease in adult transgender men receiving cross-sex hormone therapy: a systematic review","volume":"81","author":"Quintela-Castro","year":"2023","journal-title":"Nutr Rev"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.014_bib89","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025874","article-title":"Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis","volume":"9","author":"Eyawo","year":"2019","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib90","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.11159","article-title":"Clinical outcomes after acute coronary syndromes or revascularization among people living with HIV: a systematic review and meta-analysis","volume":"7","author":"Haji","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib92","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jacc.2023.04.050","article-title":"Dyslipidemia in human immunodeficiency virus disease: JACC review topic of the week","volume":"82","author":"Kalra","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.014_bib93","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.eprac.2025.07.014_bib94","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1517\/14656566.8.14.2315","article-title":"Pitavastatin: efficacy and safety in intensive lipid lowering","volume":"8","author":"Hayashi","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.014_bib95","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/annrheumdis-2015-207714","article-title":"Statin use and mortality in rheumatoid arthritis: a general population-based cohort study","volume":"75","author":"Schoenfeld","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.014_bib96","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/art.34524","article-title":"Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease","volume":"64","author":"Semb","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib97","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.24521","article-title":"Should patients with rheumatoid arthritis receive statin therapy?","volume":"60","author":"Ridker","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib98","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard.2010.136762","article-title":"Lupus Atherosclerosis Prevention Study (LAPS)","volume":"70","author":"Petri","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.014_bib99","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.30645","article-title":"Use of atorvastatin in systemic lupus erythematosus in children and adolescents","volume":"64","author":"Schanberg","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.014_bib100","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40261-017-0533-0","article-title":"Effectiveness of lipid-lowering statin therapy in patients with and without psoriasis","volume":"37","author":"Ports","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.eprac.2025.07.014_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105057","article-title":"Effect of statin use on cardiovascular events and all-cause mortality in immune-mediated inflammatory diseases: a systematic review and meta-analysis involving 148,722 participants","volume":"160","author":"Xie","year":"2020","journal-title":"Pharmacol Res"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.014_bib102","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/clc.23375","article-title":"Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: a retrospective study","volume":"43","author":"Bae","year":"2020","journal-title":"Clin Cardiol"},{"issue":"5Part A","key":"10.1016\/j.eprac.2025.07.014_bib103","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ijwd.2021.08.015","article-title":"Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis","volume":"7","author":"Keyes","year":"2021","journal-title":"Int J Womens Dermatol"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.014_bib104","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/bmt.2015.167","article-title":"Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study","volume":"50","author":"Oudin","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.014_bib105","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.bbmt.2016.12.623","article-title":"Cardiovascular risk factors in survivors of childhood hematopoietic cell transplantation treated with total body irradiation: a longitudinal analysis","volume":"23","author":"Friedman","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.014_bib106","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12020-018-1595-3","article-title":"Total body irradiation for hematopoietic stem cell transplantation during early childhood is associated with the risk for diabetes mellitus","volume":"61","author":"Nakagawa","year":"2018","journal-title":"Endocrine"},{"issue":"27","key":"10.1016\/j.eprac.2025.07.014_bib107","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2016.66.6545","article-title":"Endocrine abnormalities in aging survivors of childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"34","author":"Mostoufi-Moab","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.014_bib108","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41416-023-02410-y","article-title":"Effect of a 1-year physical activity intervention on cardiovascular health in long-term childhood cancer survivors-a randomised controlled trial (SURfit)","volume":"129","author":"Rueegg","year":"2023","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.014_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28687","article-title":"Combined resistance and aerobic exercise intervention improves fitness, insulin resistance and quality of life in survivors of childhood haemopoietic stem cell transplantation with total body irradiation","volume":"67","author":"Davis","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib110","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/S2666-7568(23)00020-X","article-title":"Frailty and sarcopenia within the earliest national Dutch childhood cancer survivor cohort (DCCSS-LATER): a cross-sectional study","volume":"4","author":"van Atteveld","year":"2023","journal-title":"Lancet Healthy Longev"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.014_bib111","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/jnci\/djad222","article-title":"Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report","volume":"116","author":"Goldberg","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib112","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaoncol.2025.0236","article-title":"Accelerated aging in survivors of childhood cancer-early onset and excess risk of chronic conditions","volume":"11","author":"Yeh","year":"2025","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.eprac.2025.07.014_bib113","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.3748\/wjg.v26.i18.2138","article-title":"Medical management of metabolic and cardiovascular complications after liver transplantation","volume":"26","author":"Becchetti","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib114","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1399-0012.2006.00555.x","article-title":"No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study","volume":"20","author":"Fellstr\u00f6m","year":"2006","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.014_bib115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12944-024-02276-w","article-title":"Efficacy and safety of statin therapy in kidney transplant recipients: a systematic review and meta-analysis","volume":"23","author":"Bellos","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.014_bib116","article-title":"Impact of statin use after heart transplantation","volume":"9","author":"Vallakati","year":"2016","journal-title":"Circulation: Heart Failure"},{"issue":"9374","key":"10.1016\/j.eprac.2025.07.014_bib117","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.014_bib118","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10741-022-10255-5","article-title":"PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis","volume":"28","author":"Jennings","year":"2023","journal-title":"Heart Fail Rev"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.014_bib119","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jaccas.2019.09.026","article-title":"Use of PCSK9 inhibitors in solid organ transplantation recipients","volume":"2","author":"Warden","year":"2020","journal-title":"JACC Case Rep"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib120","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1016\/j.jacl.2024.05.005","article-title":"Dyslipidemia management in women of reproductive potential: an expert clinical consensus from the National Lipid Association","volume":"18","author":"Agarwala","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.014_bib122","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajmg.a.30386","article-title":"Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins","volume":"131","author":"Edison","year":"2004","journal-title":"Am J Med Genet A"},{"issue":"15","key":"10.1016\/j.eprac.2025.07.014_bib123","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJM200404083501524","article-title":"Central nervous system and limb anomalies in case reports of first-trimester statin exposure","volume":"350","author":"Edison","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib124","doi-asserted-by":"crossref","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"Costantine","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib125","doi-asserted-by":"crossref","first-page":"666.e1","DOI":"10.1016\/j.ajog.2021.05.018","article-title":"A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia","volume":"225","author":"Costantine","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.014_bib126","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.121.053963","article-title":"Pravastatin versus placebo in pregnancies at high risk of term preeclampsia","volume":"144","author":"D\u00f6bert","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2025.07.014_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.09.010","article-title":"A systematic review and meta-analysis on the effects of statins on pregnancy outcomes","volume":"336","author":"Vahedian-Azimi","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.eprac.2025.07.014_bib128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2021.05.006","article-title":"Fetal toxicity associated with statins: a systematic review and meta-analysis","volume":"327","author":"Vahedian-Azimi","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.eprac.2025.07.014_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1003060","article-title":"The effect of statins exposure during pregnancy on congenital anomalies and spontaneous abortions: a systematic review and meta-analysis","volume":"13","author":"Hirsch","year":"2022","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.014_bib132","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/eurjpc\/zwad402","article-title":"Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations","volume":"31","author":"Ardissino","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.014_bib133","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"16","key":"10.1016\/j.eprac.2025.07.014_bib134","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib135","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1753495X15594082","article-title":"Severe gestational hypertriglyceridemia: a practical approach for clinicians","volume":"8","author":"Wong","year":"2015","journal-title":"Obstet Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib136","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijgo.2015.02.034","article-title":"A 23-year, single-center, retrospective analysis of 36 cases of acute pancreatitis in pregnancy","volume":"130","author":"Xu","year":"2015","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib137","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5468\/ogs.2016.59.2.148","article-title":"Hypertriglyceridemia-induced acute pancreatitis in pregnancy causing maternal death","volume":"59","author":"Jeon","year":"2016","journal-title":"Obstet Gynecol Sci"},{"issue":"17","key":"10.1016\/j.eprac.2025.07.014_bib138","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3390\/nu16172927","article-title":"Characteristics, physiopathology and management of dyslipidemias in pregnancy: a narrative review","volume":"16","author":"Formisano","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.eprac.2025.07.014_bib139","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5320156","article-title":"Determinants of maternal insulin resistance during pregnancy: an updated overview","volume":"2019","author":"Kampmann","year":"2019","journal-title":"J Diabetes Res"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib140","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib141","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jacl.2015.03.012","article-title":"Medical nutrition therapy is the essential cornerstone for effective treatment of \u201crefractory\u201d severe hypertriglyceridemia regardless of pharmaceutical treatment: evidence from a lipid management program","volume":"9","author":"Rhodes","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.014_bib142","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1210\/jc.2012-1250","article-title":"Severe hypertriglyceridemia in pregnancy","volume":"97","author":"Goldberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib143","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/01.mpa.0000202943.70708.2d","article-title":"Recurrent hypertriglyceridemia-induced pancreatitis in pregnancy: a management dilemma","volume":"32","author":"Abu Musa","year":"2006","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib144","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00000441-199504000-00005","article-title":"Successful outcome in severe pregnancy-associated hyperlipemia: a case report and literature review","volume":"309","author":"Hsia","year":"1995","journal-title":"Am J Med Sci"},{"issue":"2 Pt 2","key":"10.1016\/j.eprac.2025.07.014_bib145","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/AOG.0b013e31820755b5","article-title":"Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate","volume":"117","author":"Whitten","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.014_bib146","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00404-023-07357-2","article-title":"Fibrates and risk of congenital malformations: a nationwide cohort study in South Korea","volume":"310","author":"Kay","year":"2024","journal-title":"Arch Gynecol Obstet"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.014_bib147","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/FPC.0b013e328340095e","article-title":"Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics","volume":"20","author":"Brisson","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib148","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4158\/EP.11.5.325","article-title":"Total parenteral nutrition in management of hyperlipidemic pancreatitis during pregnancy","volume":"11","author":"Loh","year":"2005","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib149","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0016-5085(82)80144-3","article-title":"Treatment of hyperlipidemic pancreatitis in pregnancy with total parenteral nutrition","volume":"83","author":"Weinberg","year":"1982","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.014_bib150","first-page":"88","article-title":"Hypertriglyceridemia induced pancreatitis in a non-diabetic pregnant patient requiring the use of total parenteral nutrition","volume":"4","author":"Ihimoyan","year":"2011","journal-title":"Gastroenterology Res"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.014_bib151","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MOG.0000000000000956","article-title":"Medical management of hypertriglyceridemia in pancreatitis","volume":"39","author":"Gligorijevic","year":"2023","journal-title":"Curr Opin Gastroenterol"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.014_bib152","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.014_bib153","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jca.21453","article-title":"Clinical features and treatment of hypertriglyceridemia-induced acute pancreatitis during pregnancy: a retrospective study","volume":"31","author":"Huang","year":"2016","journal-title":"J Clin Apher"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:45:52Z","timestamp":1759301152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25009723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":142,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1530891X25009723"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.07.014","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Dyslipidemia \u2013 2025 Update","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}